- Fifty-seven physicians and surgeons affiliated with Dana-Farber have been named to Boston magazine's annual "Top Doctors" guide.
- Scientists analyzed tissue samples from patients who had — and had not — responded to a promising new immunotherapy drug. The study could help identify patients most likely to respond to the new drug, which blocks PD-L1.
Tags: Melanoma, Immunotherapy
- Three Dana-Farber Cancer Institute faculty are named Fellows of the American Association for the Advancement of Science (AAAS).
Tags: Appointments, Honors
- Scientists will be better able to trace how genetic changes give rise to diseases ranging from cancer to Huntington’s disease with a new map of protein-protein interactions within human cells produced by researchers at the Center for Cancer Systems Biology (CCSB) at Dana-Farber and associates around the world.
Tags: Genomics, Genetics
- A research team led by Dana-Farber Cancer Institute and Brigham and Women’s Hospital has uncovered surprising new findings that underscore the role of an important signaling pathway, already known to be critical in cancer, in the development of type 2 diabetes.
- In a major advance in the care of patients with leukemia and other blood disorders, physicians at Dana-Farber/Brigham and Women's Cancer Center have begun using Rapid Heme Panel, a high-tech genetic test that provides, within a matter of days, an unprecedented amount of critical information to aid the choice of treatment.
Tags: StemCellTransplant, TranslationalResearch, Leukemia
- Researchers have found a way to defeat one of the most tantalizing yet elusive target proteins in cancer cells by turning the protein's own molecular machinations against it. In a study published online by the journal Cell, the scientists used a specially crafted compound to disrupt the protein's ability to rev up its own production and that of other proteins involved in tumor cell growth.
Tags: ChildhoodCancer, TargetedTherapy, TranscriptionFactors
- Dana-Farber Cancer Institute and Astellas Pharma Inc. today announced a three-year collaboration to research and develop small molecule inhibitors of oncogenic K-Ras for the treatment of cancer, including lung cancer.
Tags: LungCancer, Partnerships
- Researchers reported survival of patients with advanced melanoma was improved when they received an immune stimulant along with a checkpoint blocker immunotherapy drug. The combination also resulted in fewer serious side effects compared with patients who got only the immunotherapy drug, ipilimumab.
Tags: Melanoma, Immunotherapy
- David G. Nathan, MD, president emeritus of Dana-Farber Cancer Institute and physician-in-chief emeritus of Boston Children's Hospital, was honored as the inaugural recipient of the Boston Children’s Hospital Lifetime Impact Award at the hospital’s second Annual Global Pediatric Innovation Summit, Taking on Tomorrow (#PedInno14).
Tags: ChildhoodCancer, Honors
Showing 31-40 of 575 items